Ultrasensitive BCMA CARs Deliver Responses With Tolerable Safety in R/R Multiple Myeloma
The use of the BCMA-directed CAR T-cell therapy D8 Fab CAR and the dual-targeting AUTO8 CAR T-cell therapy is safe and feasible in patients with relapsed/refractory multiple myeloma.
Source: onclive.com